StockLens

Zydus Lifesciences Limited (ZYDUSLIFE) share price and analysis

ZYDUSLIFE last traded at ₹1,204.20 (+1.02%) on the NSE. Market cap ₹1,20,119 Cr (Large cap), Pharma & Healthcare sector.

Overall rating: 6.6/10 (Good)

Long-term view: Good for long-term. More strengths than weaknesses for a multi-year hold. Trade bias (next few weeks): Strong long. Trend and momentum are clearly pointing up.

Strengths of ZYDUSLIFE

Weaknesses of ZYDUSLIFE

Key numbers

NumberValueAssessmentNormal range
P/E (TTM)28.8Cheaper than peers37.0–49.3 (sector median 41.1)
Forward P/E24.4Profits expected to growbelow today's P/E (28.8) and near 41
Price / book4.32Normal2–6
EPS (TTM)₹41.85Profitableabove ₹0
Return on equity14.7%Average15%+ (below 10% is weak)
Debt / equity0.46Low debtbelow 1.0 (under 0.5 is great)
Net margin13.8%Healthy10%+ (below 5% is thin)
Operating margin17.2%Average20%+ strong, below 10% thin
Revenue growth+29.2%Growing well10%+ a year (below 3% is weak)
Profit growth-25.8%Falling10%+ a year (falling is weak)
Dividend yield0.08%Small payout1.5%+ (none is fine for growth firms)
Current ratio1.02Adequate1.5+ (below 1 is tight)
52W high₹1,266.605% below · near the highprice in the top 40% of its 52-week range
52W low₹835.50Price is 44% above it
50-DMA₹1,161.40Price 3.7% aboveprice above it = short-term uptrend
200-DMA₹1,050.36Price 14.6% aboveprice above it = long-term uptrend
1Y return+27.0%Beat the Nifty 50Nifty 50 did −0.4%
Beta0.31Steadier than the market0.8–1.3 (1 = moves with market)
Promoter / insider75.2%Owners have a big stake50%+ shows owner commitment
Institutions16.2%Moderate interest30%+ is strong
Analyst target₹1,233.122.4% upside · 29 analysts8%+ upside

Questions about ZYDUSLIFE

What is the share price of Zydus Lifesciences Limited (ZYDUSLIFE) today?

ZYDUSLIFE last traded at ₹1,204.20 (+1.02% on the day) on the NSE. Its 52-week range is ₹835.50 to ₹1,266.60. Prices are delayed and come from Yahoo Finance.

Is ZYDUSLIFE a good stock for the long term?

StockLens rates ZYDUSLIFE 6.6 out of 10 (Good) overall. Its long-term verdict is "Good for long-term": More strengths than weaknesses for a multi-year hold. Strengths: uptrend, revenue growth, bullish moving averages. Concerns: falling profits.

Is ZYDUSLIFE share overvalued?

ZYDUSLIFE trades at a P/E of 28.8 against a Pharma & Healthcare median of 41.1, which StockLens rates as "Cheaper than peers". Its price-to-book ratio is 4.32.

Is ZYDUSLIFE good for short-term trading?

The trade bias for the next few weeks is "Strong long": Trend and momentum are clearly pointing up. The price is 14.6% above its 200-day average and 14-day RSI is 56.

Which stocks are similar to ZYDUSLIFE?

Similar Pharma & Healthcare stocks of comparable size include Dr. Reddy's Laboratories, Apollo Hospitals, Laurus Labs, Cipla, Aurobindo Pharma. You can compare up to 4 of them side by side on StockLens.

About Zydus Lifesciences Limited

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Consumer Products, and Medical Technologies. The company offers active pharmaceutical ingredients, human and finished dosage formulations, generics, branded generics, specialty formulations, biosimilars, vaccines, novel therapeutics, medical devices and technologies, consumer wellness, veterinary, and animal health products. It also provides biological products in the areas of oncology, autoimmune disorders, nephrology, inflammation, rheumatology, hepatology, and infectious diseases; and designs and executes clinical trials across new chemical entities (NCEs), biologics, vaccines, and specialty generics. In addition, the company operates seasonal, skin and healthcare, and food and nutrition products under the Glucon D, Complan, Sugar Free, Nycil, Everyuth, Nutralite, and RiteBite Max Protein brands. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.

Stocks similar to ZYDUSLIFE

Compare ZYDUSLIFE with DRREDDY, APOLLOHOSP, LAURUSLABS

Educational information, not investment advice. Data from Yahoo Finance and NSE Indices; prices may be delayed.